HEPATITIS C VIRUS (HCV) GENOTYPE TESTING
|
|
- Willa Watson
- 6 years ago
- Views:
Transcription
1 CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS Effective Date: January 1, 2015 Table of Contents Page GUIDELINES 1 BACKGROUND 1 CLINICAL EVIDENCE 2 Guidelines and Recommendations 4 US FOOD AND DRUG ADMINISTRATION (US FDA) 5 CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) 5 APPLICABLE CODING 6 REFERENCES 7 POLICY HISTORY/REVISION HISTORY 9 INSTRUCTIONS FOR USE Physician Decision Support (PDS) is a lab ordering tool operated by BeaconLBS. This Clinical Guideline supports the Questions and Answers that appear in PDS for tests referenced in this document. UnitedHealthcare reserves the right, in its sole discretion, to modify its Clinical Guidelines as necessary. This Clinical Guideline is provided for informational purposes. It does not constitute a Medical Policy or medical advice. GUIDELINES BeaconLBS recommends the use of Hepatitis C virus (HCV) genotype testing within 12 weeks prior to initiation of interferon- based treatment. These recommendations are consistent with current evidence-based guidelines from the European Association for the Study of the Liver (EASL), US Preventive Task Force (USPSTF), and the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). BACKGROUND Currently, HCV genotype testing is used clinically to predict response to interferon-based therapy, to determine optimal treatment duration, to determine the appropriate dose of ribavirin, and to identify patients eligible for treatment with new direct acting antivirals. Since 2002, the standard of care (SOC) treatment for hepatitis C has been pegylated interferon and ribavirin. 1 Nonetheless, interferon-based therapy has had limited success. It is estimated that 20-50% of patients treated with pegylated interferon and ribavirin will not achieve sustained Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 1
2 virologic response. 2 Viral genotype is the strongest predictor of response to interferon-based therapies, 3 and current SOC treatment algorithms have been established based on specific viral genotypes. There are at least six genotypes (genotypes 1-6) of HCV, and these differ by 30-35% in nucleotide sequence; these major genotypes can be further subdivided into subtypes (a,b,c,d ) that differ by up to %. 4 The prevalence of viral genotypes varies with geography. Genotype 1 is prevalent in the US and Europe. Genotypes 3 and 4 are seen in Europe in the intravenous drug abuse population. Genotype 4 has frequently been isolated in North Africa. Genotype 2 is more prevalent in the Mediterranean region. Genotypes 5 and 6 are rare. Globally, most cases of HCV are genotype 1 infections, 5 and in the US, 77% of cases are genotype 1 infections. 6 HCV genotype may play a role in the risk for disease progression. 7 Recent studies suggest that patients with genotype 3 are at higher risk for a more rapid progression to liver fibrosis 8 and have an increased risk for developing hepatocellular carcinoma. 9 New direct acting antiviral therapies have been introduced to improve response in patients with genotype 1. Boceprevir and telaprevir target a specific enzyme required for the virus life cycle. They are serine protease inhibitors that bind reversibly to the NS3 active site. CLINICAL EVIDENCE HCV Treatment Cure rates with SOC, interferon-based therapy varies according to genotype, with genotypes 3, 5, and 6 achieving sustained virologic response (SVR) in over 80% of patients, and genotype 2 achieving SVR in about 80% of patients. Genotype 4 achieves SVR in slightly greater than 40% of cases. Genotype 1, the most prevalent genotype worldwide, has the lowest response rate to SOC therapy, at about 40%. 5 Studies of therapeutic responses in individuals infected with various genotypes have produced recommendations for pegylated interferon plus ribavirin treatment duration that are based on genotype. These studies look at response to therapy at certain critical treatment milestones in order to predict response. Patients with genotypes 2 and 3 require 24 weeks of SOC therapy to obtain sustained virologic response, whereas those individuals with genotypes 1 10 and 4 require 48 weeks of therapy. 11 HCV genotyping and quantitative HCV RNA determinations provide prognostic information regarding likelihood of response, help optimize selection and dosing of treatment, provide information on optimal treatment duration, and help identify time points when therapy should be discontinued. 2, 5 A recent meta-analysis of seven randomized, controlled trials concluded that patients with genotype 1 may have their SOC treatment course shortened to 24 weeks if they have a rapid virologic response characterized by undetectable HCV RNA at 4 weeks of therapy and if their baseline HCV viral load is low. 5,12 An international panel has made a similar recommendation 13 for shortening treatment course for patients with genotype 4 when a rapid virologic response is observed. Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 2
3 Ribavirin dosing is standardized to genotype. 5 In a phase III, randomized, multicenter, double-blind clinical trial, it was established that patients with genotype 1 require weight-based dosing of ribavirin and that patients with genotype 2 and 3 can be treated with a lower dose over a shorter treatment course. 14 New direct acting antiviral drugs are specifically indicated for the treatment of HCV genotype 1 patients who tend to be more refractory to standard pegylated interferon plus ribavirin therapy. 15 These agents, when combined with pegylated interferon and ribavirin, attain SVR rates ranging from 63 to 75% among treatment naïve individuals. 15 The treatment algorithm for each direct acting antiviral utilizes response guided therapy to determine the duration of treatment, often allowing for 24 rather than 48 weeks of therapy. Laboratory Testing HCV genotyping can be performed by two general methodologies: direct sequencing and reverse hybridization. Direct sequencing looks at the full sequence of a particular region of the HCV genome; reverse hybridization is restricted to the identification of specific nucleotides at limited positions, which are associated with a particular genotype or subtype. Line probe assays are a type of reverse hybridization that uses oligonucleotide probes. Of the commercially available HCV genotype tests, Trugene 5 NC HCV Genotyping Kit (Siemens Medical Solutions Diagnostics) is a direct sequencing assay and VERSANT HCV Genotype 2.0 Assay (Siemens Medical Solutions Diagnostics) is a line probe assay 16. Commercial assays target the 5 noncoding region (NCR) of the HCV genome because it is highly conserved. This target is useful for differentiating between genotypes; although it cannot reliably distinguish subtypes (e.g. 1a from 1b) and also may not reliably differentiate genotype 1 from the rarely occurring genotype Newer versions of the commercially available assays target other regions of the genome to provide better characterization of genotype and subtype. For example, the Versant HCV Genotype 2.0 line assay (INNO-LiPA HCV 2.0), which targets the 5 NCR and core regions, shows improved characterization of genotype 6 compared to the earlier version of the assay. 18 Abbott has introduced a real-time PCR based assay that targets both the 5 NCR and the NS5B gene. (NS5B is a viral protein required for replication.) A study comparing this assay to the Versant HCV Genotype 2.0 assay found good correlation between the assays. 11 Current methods cannot provide correct genotyping in a minority (3%) of cases. 2 Mixed genotypes are uncommon and their clinical significance remains to be established. 11 Viral subtype data will likely need to be evaluated in order to study newer therapies that target specific HCV enzymes. It has been suggested that genotyping assays based only on the 5 NCR should not be used for clinical trials requiring genotypic subtyping. 17 The Abbott RealTime HCV Genotype II assay is reported to identify 93.2 % of subtype 1a and 88.9% of subtype 1b strains. 17 The newer (2.0) version of the Versant assay has been reported to correctly subtype all genotype 3 subtypes, the majority of subtype 1 samples, but not subtypes for genotypes 2 and The same study reports that a new HCV NS5b sequencing assay could subtype all samples not identified with 5 NCR assays. An NS5B microarray-based technique has been reported to have 100% genotyping concordance with gold standard phylogenetic analysis of the NS5B region and 99.7% concordance with the standard for subtyping. 20 Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 3
4 Guidelines and Recommendations Current clinical guidelines from societies regarding HCV genotype testing follow, and it should be noted that the most recent guidelines (published in 2011) were written after the phase III trials of boceprevir and telaprevir, two new direct acting antiviral drugs. 21 The statement about standard of care therapy is in reference to interferonbased treatment. American Association for the Study of Liver Diseases (AASLD) The following recommendation derives from the American Association for the Study of Liver Diseases 2011 guidelines for treatment of genotype 1 HCV infections with new direct acting drugs: 22 Patients with genotype 1 infections should be treated with a direct acting antiviral, boceprevir or telaprevir, plus peg interferon alfa and ribavirin. This recommendation is from the American Association for the Study of Liver Disease, 2 published in 2009: HCV genotype testing should be performed in all patients prior to treatment with interferonbased therapy to establish dose and length of treatment course and to predict probability of sustained virologic response. American Association for the Study of Liver Diseases and Infectious Diseases Society of America Recent 2014 guidelines from American Association for the Study of Liver Diseases and Infectious Diseases Society of America state that: 22 The following laboratory test is recommended within 12 weeks of starting antiviral therapy: HCV genotype and quantitative HCV viral load Quantitative HCV viral load testing is recommended after 4 weeks of therapy, at the end of treatment, and at 12 weeks following completion of therapy. Quantitative HCV viral load monitoring at 4 weeks is recommended, but discontinuation of treatment because this test result is missing is NOT recommended. European Association for the Study of the Liver (EASL) The following recommendation derives from the most recent European Association for the Study of the Liver clinical practice guidelines, 5 published in 2011: HCV viral genotype should be determined prior to antiviral therapy. For standard of care therapy, additional subtyping is not necessary. The following recommendations are derived from the most recent European Association for the Study of the Liver (EASL) clinical practice guidelines on the Management of Hepatitis C Virus infection, published in : HCV RNA detection and measurement should be made by a sensitive assay, lower limit detection of <15 IU/ml). HCV genotype must be determined prior to treatment initiation, subtyping of genotype 1a/1b may be relevant to PI-based triple therapy. Combination of pegylated IFN-α and Ribavirin is the approved standard of care for chronic hepatitis C genotype 2, 3, 4, 5, and 6. IL28B genotyping is not a prerequisite for treating hepatitis C. Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 4
5 During triple therapy in HCV genotype 1 patients, HCV RNA should be measured at weeks 4, 8, 12, 24, and at the end of treatment, when giving boceprevir. At weeks 4, 12, 24 and end of treatment, when giving telaprevir. During dual therapy, HCV RNA quantification should be measured at baseline, weeks 4, 12, 24 and end of treatment. At the end of treatment, virological response and SVR at week 12 or 24 must be assessed. Full adherence to all antiviral drugs should be the objective, in order to achieve optimum SVR and to reduce the risk of emergence of specific drug resistance. Obesity has an adverse effect on pegylated IFN-α and Ribavirin treatment. Weight control is recommended before initiating the treatment and may increase the likelihood of SVR. HCV genotype 1 infected patients who failed to eradicate HCV on prior treatment with dual therapy should be retreated with the triple combination. Patient with cirrhosis should undergo regular surveillance for HCC, irrespective of SVR. US Preventive Services Task Force (USPSTF) The following recommendations derived from the most recent publication by the US Preventive Services Task Force (USPSTF) on screening for and treatment of hepatitis C virus infection in asymptomatic adults 24. Screening for HCV in high risk patients including but not limited to past or current injection drug users, receiving blood transfusion before 1992, long term hemodialysis, born to an HCV infected mother, incarceration and intranasal drug use. One time screening for HCV infection to adults born between 1945 and Detection of Anti-HCV antibodies, followed by a confirmatory real-time PCR assay testing accurately identifies patients with chronic HCV infection. Screening intervals for continued high risk patients should be periodic; however, evidence on frequency of screening in these persons is lacking. Quantitative HCV RNA testing should be performed 24 weeks after treatment cessation to confirm sustained virologic response for patients who have undetectable HCV RNA at the end of an antiviral regimen. US FOOD AND DRUG ADMINISTRATION (US FDA) There are several FDA approved nucleic acid based assays for the detection and monitoring of HCV. If a test is used that has not been cleared or approved by the FDA, the performing institution must determine the performance characteristics. CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) For Medicare populations, CMS does not pay for screening procedures (tests) performed in the absence of signs or symptoms. (Section 1862(a)(7) of the Social Security Act) Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 5
6 There are several CMS policies that apply to HCV Testing (Prognosis, including Monitoring). In some cases, CMS reimbursement is limited to FDA approved and laboratory developed tests (LDT) only. Physicians should consult their state s regulations. APPLICABLE CODING CPT Code Genotype, DNA, hepatitis C Description Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 6
7 REFERENCES 1. Fried MW, Shiffman ML, et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England journal of medicine, (13): p Ghany MG, Strader DB, et al., Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, Md.), (4): p Scott JD and Gretch DR, Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA, (7): p Simmonds P, Genetic diversity and evolution of hepatitis C virus--15 years on. The Journal of general virology, (Pt 11): p Craxi A and J., EASL clinical practice guidelines: management of hepatitis C virus infection : p Hepatitis C virus. Figure 14. Laboratory Corporation of America Web site. BB HA89A81BPc1NvY3dfQ_2CbEdFAO5Gt_4!/?WCM_PORTLET=PC_7_UE4S1I9308G950IMN50RQC20S4_WC M &WCM_GLOBAL_CONTEXT=/wps/wcm/connect/labcorp+content/LabCorp/Education+and+Research/Rese arch/virology/hepatitis+viruses/hepatitis+c+virus. (Accessed November 17, 2011.). 7. Chayama K and Hayes CN, Hepatitis C virus: How genetic variability affects pathobiology of disease. Journal of gastroenterology and hepatology, Suppl 1: p Probst A, Dang T, et al., Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. Journal of viral hepatitis, (11): p Nkontchou G, Ziol M, et al., HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. Journal of viral hepatitis, (10): p. e McHutchison JG, Gordon SC, et al., Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. The New England journal of medicine, (21): p Ciotti M, Marcuccilli F, et al., A multicenter evaluation of the Abbott RealTime HCV Genotype II assay. Journal of virological methods, (2): p Moreno C, Deltenre P, et al., Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. Journal of hepatology, (1): p Khattab MA, Ferenci P, et al., Management of hepatitis C virus genotype recommendations of an international expert panel. 54, 2011: p Hadziyannis SJ, Sette H, et al., Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of internal medicine, (5): p Ghany MG, Nelson DR, et al., An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 7
8 (Baltimore, Md.), (4): p Chevaliez S, Virological tools to diagnose and monitor hepatitis C virus infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, (2): p Chevaliez S, Bouvier-Alias M, et al., Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PloS one, (12): p. e Bouchardeau F, Cantaloube JF, et al., Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. Journal of clinical microbiology, (4): p Stelzl E, van der Meer C, et al., Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays. Clinical chemistry and laboratory medicine : CCLM / FESCC, (2): p Gryadunov D, Nicot F, et al., Hepatitis C virus genotyping using an oligonucleotide microarray based on the NS5B sequence. Journal of clinical microbiology, (11): p Rosen HR, Clinical practice. Chronic hepatitis C infection. The New England journal of medicine, (25): p Hepatitis C, American Association For the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). Recommendations for Testing, Managing, and Treating Available at: or (Accessed: October 2014). 23. Easl and J., David Mutimer. Practice Guidelines Management of hepatitis C virus infection, 2014: p Moyer VA and Force USPST, Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine, (5): p Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 8
9 POLICY HISTORY/REVISION HISTORY Date Action/Description 11/ Annual Policy Review Completed no changes. 10/23/2014 Reference added in reference section: American Association For the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: or nes.pdf (Accessed: October 21, 2014). Within the body of the policy, in the "BeaconLBS Recommendations" section, clarifying language was added. The recommendation itself has not changed. Within the body of the policy, in the "Guidelines and Recommendations" - "American Association for the Study of Liver Diseases (AASLD)" section, the following was added: "Recent 2014 guidelines from American Association for the Study of Liver Diseases and Infectious Diseases Society of America state that: The following laboratory test is recommended within 12 weeks of starting antiviral therapy: - HCV genotype and quantitative HCV viral load Quantitative HCV viral load testing is recommended after 4 weeks of therapy, at the end of treatment, and at 12 weeks following completion of therapy. Quantitative HCV viral load monitoring at 4 weeks is recommended, but discontinuation of treatment because this test result is missing is NOT recommended." Proprietary Information of UnitedHealthcare. Copyright 2015 United HealthCare Services, Inc. Page 9
QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA Policy Number: PDS - 028 Effective Date:
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS
HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS I. Qattan Centres for Hepatology, Royal Free & University College Medical School, London V. Emery Department of Virology, Royal Free & University
More informationon October 4, 2018 by guest
JCM Accepts, published online ahead of print on 3 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.01249-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Title: Performance of
More informationTHE CHANGING LANDSCAPE OF HEPATITIS INFECTION. Michael E. Herman D.O.
THE CHANGING LANDSCAPE OF HEPATITIS INFECTION Michael E. Herman D.O. What s New? For Primary Care Providers Importance of diagnosing HCV For HCV Treaters How can we improve current therapies? For everyone
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationVirological assessment of patients candidate to DAA
Virological assessment of patients candidate to DAA Patients characteristics Italian male patient Diagnosis of chronic HCV infection in 1994 Genotype 1b defined in 1998 Non-responder to IFN+RBV He developed
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHarvoni: solution to HCV
Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationAMERICAN GASTROENTEROLOGICAL ASSOCIATION DIGESTIVE HEALTH RECOGNITION PROGRAM IN COLLABORATION WITH CECITY. Non-PQRS Narrative Measure Specifications
AMERICAN GASTROENTEROLOGICAL ASSOCIATION DIGESTIVE HEALTH RECOGNITION PROGRAM IN COLLABORATION WITH CECITY Non-PQRS Narrative Measure Specifications 1 Table of Contents AGA DHRP CRC Measure #1: Colonoscopy
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationJOHNS HOPKINS HEALTHCARE
JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationHepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid
Hepatitis C Virus Clinical Criteria Update September 18, 2014 For: New York State Medicaid 1 Purpose Characterize the place in therapy for the agents utilized for management of chronic hepatitis C (CHC)
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationCurrent Standard of Care for Naïve HCV Patients (SVR)
Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 3
National Clinical Guidelines for the treatment of HCV in adults Version 3 January 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationAntiviral Therapy 2014; 19: (doi: /IMP2723)
Antiviral Therapy 214; 19:449 454 (doi: 1.3851/IMP2723) Original article Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2. and the Abbott RealTime hepatitis C assays implications for
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationThe Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy
280 POSITION PAPER : BELGIAN WORKING GROUP FOR HEPATITIS C The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy P. Stärkel 1, D. Vandijck 2,3, W. Laleman 4,
More informationAntiviral therapy guidelines for the general population
Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationHepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas
Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationBible Class: HCV Infection
Bible Class: HCV Infection PD Dr. Dr. med. Nasser Semmo UVCM, Hepatology What is the HCV prevalence and incidence? 2 HCV Prevalence Worldwide about 120-210 Mio. infected with HCV, about 9 Mio. in Europe,
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationQué aporta el laboratorio a la terapia del VHC en 2015?
Qué aporta el laboratorio a la terapia del VHC en 2015? Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña HCV Medicine in 2015 Liver function & fibrosis Molecular
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 01/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationCost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection
Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding the cost
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationInfergen Monotherapy. Infergen (interferon alfacon-1) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy
More information